CoChat
Sign Up
Cited by 1,633Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Davis, Ian D., Martin, Andrew J., Stockler, Martin R., Begbie, Stephen, Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy, Pook, David W., Reaume, M. Neil, Sandhu, Shahneen K., Tan, Alvin, Tan, T. Hsiang, Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G., Yip, Sonia, Zhang, Alison Y., Zielinski, Robert R., Sweeney, Christopher J.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1903835
Open this paper in CoChat — free account

Abstract

BACKGROUND: Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer. METHODS: In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point was overall survival. Secondary end points included progression-free survival as determined by the prostate-specific antigen (PSA) level, clinical progression-free survival, and adverse events. RESULTS: A total of 1125 men underwent randomization; the median follow-up was 34 months. There were 102 deaths in the enzalutamide group and 143 deaths in the standard-care group (hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.86; P = 0.002). Kaplan-Meier estimates of overall survival at 3 years were 80% (based on 94 events) in the enzalutamide group and 72% (based on 130 events) in the standard-care group. Better results with enzalutamide were also seen in PSA progression-free survival (174 and 333 events, respectively; hazard ratio, 0.39; P<0.001) and in clinical progression-free survival (167 and 320 events, respectively; hazard ratio, 0.40; P<0.001). Treatment discontinuation due to adverse events was more frequent in the enzalutamide group than in the standard-care group (33 events and 14 events, respectively). Fatigue was more common in the enzalutamide group; seizures occurred in 7 patients in the enzalutamide group (1%) and in no patients in the standard-care group. CONCLUSIONS: Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression. The enzalutamide group had a higher incidence of seizures and other toxic effects, especially among those treated with early docetaxel. (Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; ClinicalTrials.gov number, NCT02446405; and EU Clinical Trials Register number, 2014-003190-42.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1903835

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

Sorted by citations

See all 1,633

Related

Metadata

Authors
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G., McCaffrey, J., McDermott, R., McJannett, M., North, S. A., Parnis, F., Parulekar, W., Pook, D. W., Reaume, M. N., Sandhu, S. K., Tan, A., Tan, T. H., Thomson, A., Tu, E., Vera-Badillo, F., Williams, S. G., Yip, S., Zhang, A. Y., Zielinski, R. R., & Sweeney, C. J.
Affiliations
  • The University of Sydney (AU)
  • University College Dublin (IE)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2019-07-11
Volume
381
Issue
2
Pages
121-131
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1903835
OpenAlex
W2947893479
Cited by
1,633
References
25
Citations by year
2026: 166 · 2025: 217 · 2024: 228 · 2023: 244 · 2022: 276 · 2021: 253 · 2020: 192 · 2019: 49
FWCI
141.62
Type
journal article
Language
en
Open access
closed
Licence
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders
  • Canadian Cancer Society (704970)
  • Cancer Australia (Support for Cancer Clinical Trials Program)
  • National Health and Medical Research Council (Practitioner Fellowship APP1102604, Program Grants 1037786 and 1150467)
  • Astellas Scientific and Medical Affairs
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
enzalutamide, metastatic hormone-sensitive prostate cancer, androgen receptor antagonists, testosterone suppression, docetaxel, nonsteroidal antiandrogens, overall survival, progression-free survival, prostate-specific antigen, seizures, fatigue, adverse events, first-line therapy, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer
MeSH terms
Progression-Free Survival, Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Bone Neoplasms, Digestive System Neoplasms, Fatigue, Follow-Up Studies, Humans, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Seizures, Kaplan-Meier Estimate, Androgen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review